Insmed D
D
INSM
159.590
USD
-0.52
(-0.32%)
مغلق
حجم التداول
52,590
الربح لكل سهم
-6
العائد الربحي
-
P/E
-28
حجم السوق
33,733,302,098
العنوان: Insmed
القطاع: Healthcare
الصناعة: Biotechnology
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.